SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is trending due to a massive volume spike and price surge, triggering multiple trading halts, as community discussion focuses on its extremely low float and high insider ownership for a potential short squeeze. Many are comparing it to recent explosive SPACs, with speculative targets suggesting significant upside, fueled by talking points like a rumored "sex toy manufacturer" acquisition. The stock's momentum reflects its position as a key play in the current "SPAC mania" for micro-float tickers.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is rapidly trending due to a potent combination of its extremely low share float and a potential short squeeze, driving significant momentum. The recent announcement of a strategic manufacturing partnership, expected to boost production margins, further amplifies investor interest. The community is actively discussing strong buying defense and a "textbook" short squeeze play as the company continues to expand global adoption of its fingerprint drug screening technology.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings (ONDS) is trending due to recent autonomous system orders and the FCC's ban on foreign-made drones, which significantly boosts its role in the domestic market. The community is actively discussing a potential short squeeze and anticipating a significant price breakout, with many seeing dips as buying opportunities. This positions Ondas as a crucial player in the growing defense and critical infrastructure sectors for autonomous and counter-drone solutions.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending after the FDA issued a Complete Response Letter for its relacorilant hypertension indication, triggering a sharp stock decline and intense community debate. Investors are divided, with many viewing the sell-off as an overreaction given the company's existing profitable drug and other pipeline programs, while others express caution regarding potential delays and future prospects.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals (VNDA) is trending following its recent FDA approval of NEREUS, the first new motion sickness treatment in over four decades, validating a significant pipeline asset. Community discussion highlights the drug's broader potential for GLP-1 induced nausea, fueling speculation of substantial upside, a potential short squeeze, and even a buyout, given the company's strong financial standing and additional upcoming regulatory catalysts.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending following its CEO's strategic insights on CNBC and news of spinning off its cloud business into ChronoScale, a move seen by many as unlocking significant value and clarifying its pure-play AI data center infrastructure focus. The community is actively discussing sustained demand from hyperscalers and strong analyst confidence ahead of its upcoming earnings report, fueling bullish sentiment despite recent price volatility. This strategic realignment aims to capitalize on the booming AI infrastructure market with a clearer business model and substantial contracted revenue.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amidst a wave of strong bearish sentiment, largely attributed to sustained selling pressure, high short interest, and year-end tax loss harvesting. The community is actively discussing the recent FDA approval of Novo Nordisk's oral Wegovy pill, seeing a potential for partnership and a significant catalyst for HIMS's future growth in GLP-1 offerings, alongside its ongoing expansion in D2C lab testing and international markets. Despite current frustration, many long-term investors are using this dip as a buying opportunity, anticipating a strong reversal.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending after rival Corcept Therapeutics received an FDA Complete Response Letter for its Cushing's syndrome drug, effectively removing a near-term competitor for Xeris's Recorlev. The community is buzzing with bullish sentiment, emphasizing Recorlev's blockbuster potential and the significant undervaluation of XERS, further supported by advancing pipeline assets like XP-8121 and robust gross margins.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending due to the FDA's acceptance and priority review of its supplemental New Drug Application for AXS-05 in Alzheimer's disease agitation, with an action date anticipated in the near future. This significant regulatory milestone, combined with growing sales of its existing CNS therapies like Auvelity, has ignited immense optimism within the community, with many anticipating substantial long-term value and discussing breakthrough potential.

Motorola Solutions, Inc. engages in the provision of communication infrastructure, devices, accessories, software, and services. It operates through the Products and Systems Integration and Software and Services segments. The Products and Systems Integration segment includes a portfolio of infrastructure, devices, accessories, and video security devices, and the implementation and integration of such systems, devices, and applications. The Software and Services segment focuses on the public safety and enterprise Command Center Software, unified communications applications, and video software solutions. The company was founded on September 25, 1928 and is headquartered in Chicago, IL.

Motorola Solutions Inc

Motorola Solutions ($MSI) is trending following strategic acquisitions in advanced communications and AI-powered video monitoring, reinforcing its leadership in mission-critical technology for public safety and enterprise security. Community sentiment reflects a strong focus on institutional accumulation, evident in large dark pool trades and technical indicators suggesting the stock is oversold, signaling potential for a reversal.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Markets extended a strong multi-year bull run, with the S&amp;P 500 posting solid double-digit gains and leadership concentrated in tech and communication services.</li><li>Retail traders remain divided, with roughly 40% expecting flat or negative year-end returns despite the market’s recent rebound.</li><li>Strategists see earnings growth, AI adoption, and resilient economic growth supporting 2026 upside.</li></ul>The futures market is yet to react significantly to the inflation reading. The CME FedWatch Tool, based on futures traders' expectations, still shows more than 75% odds of a pause at the January meeting. Economists, though positive about the Federal Reserve lowering rates further next year, were divided on whether a reduction will materialize in January.Where does this all leave the market, which is now in its fourth year of a bull run? Will Santa arrive on Wall Street on time to give the market the typical year-end lift? Will 2026 prove to be another bumper year for stocks?For the unversed, a Santa rally is a calendar effect in the stock market that drives sustained upside in the final five sessions of a year and the first two sessions of the following year. So, it starts on the 24th of this month, an abbreviated session ahead of the Dec. 25 Christmas holiday, and runs through Jan. 5.&nbsp;Historical trends prove that:<figure class="image"><img style="aspect-ratio:519/245;" src="https://news.stocktwits-cdn.com/4ee6dbb33419f5d505fe4641cde8e32b_6cb09028aa.webp" alt="4ee6dbb33419f5d505fe4641cde8e32b.webp" width="519" height="245"></figure>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp;Source: Sevens Report via Investing.com&nbsp;<h2 class="st-heading-2">Market Check-In</h2>After the 2022 inflation-driven economic uncertainty drove the market into bear territory, it hit a bottom in October before bouncing back strongly.<h4 class="st-heading-4" style="text-align:center;">&nbsp;S&amp;P 500 Returns&nbsp;</h4><figure class="table" style="width:42.48%;"><table class="ck-table-resized"><colgroup><col style="width:27.81%;"><col style="width:72.19%;"></colgroup><tbody><tr><td>Year</td><td>Annual Returns</td></tr><tr><td>2025 (YTD)</td><td>+15.2%</td></tr><tr><td>2024</td><td>+23.3%</td></tr><tr><td>2023</td><td>+24.2%</td></tr><tr><td>2022</td><td>-19.4%</td></tr></tbody></table></figure>Among the 11 S&amp;P 500 sectors, communication services and IT have outperformed this year, with gains of&nbsp;more than 20%.&nbsp;<h4 class="st-heading-4" style="text-align:center;">S&amp;P 500 Sectors’ YTD Returns</h4><figure class="table" style="width:42.91%;"><table class="ck-table-resized"><colgroup><col style="width:71.47%;"><col style="width:28.53%;"></colgroup><tbody><tr><td>Sectors</td><td>Returns</td></tr><tr><td>Communication Services</td><td>+30.0%</td></tr><tr><td>IT</td><td>+20.6%</td></tr><tr><td>Industrials</td><td>+16.9%</td></tr><tr><td>Utilities</td><td>+13.2%</td></tr><tr><td>Financials</td><td>+12.5%</td></tr><tr><td>Healthcare</td><td>+11.4%</td></tr><tr><td>Materials</td><td>+7.4%</td></tr><tr><td>Consumer Discretionary</td><td>+7.2%</td></tr><tr><td>Consumer Staples</td><td>+2.6%</td></tr><tr><td>Energy</td><td>+2.5%</td></tr><tr><td>Real Estate</td><td>-0.9%</td></tr></tbody></table></figure>&nbsp;Indices, representing different market class categories, have had a solid run this year, although the broader tech sector and the narrower non-financial tech categories have been outperforming slightly.<img src="https://news.stocktwits-cdn.com/Market_YTD_Performance_png_3f6ee6c7e9.webp" alt="Market YTD Performance.png">Source: Koyfin<h2 class="st-heading-2">Retail Hopes But Stays Skeptic</h2>Not all retail traders are convinced that Santa will work his magic on Wall Street.&nbsp;An ongoing Stocktwits poll asking users about their expectations for the S&amp;P 500's potential return in the second half of December showed that nearly 40% of retail traders are bracing for either a flat or negative performance. A little over 60% expect the market to end the year with a gain.<figure class="image"><a href="https://stocktwits.com/discussions/what-do-you-expect-the-sp-500s-total-return-to-be-in-the-second-half-of-december/639317564"><img style="aspect-ratio:725/608;" src="https://news.stocktwits-cdn.com/S_Tpol_png_f5aa234af8.webp" alt="STpol;.png" width="725" height="608"></a></figure>It is worth noting that many of the votes were cast before the November inflation report was released on Thursday. On the polls timeline, a bearish user wrote, “The market is way overvalued.”His views aligned with those of NYSU Stern School of Business Finance and Economics Professor Aswath Damodaran, famously known as the “Dean of Valuation”. In an interview with CNBC last week, Damodaran said:<blockquote>“I’m not sure the remaining 493 [of the S&amp;P 500 stocks] are bargains relative to the Mag-7. They looked richly priced to me as well.”</blockquote><h2 class="st-heading-2">Inflation Adds Spring To Santa’s Steps</h2>The November inflation report showed a cool-off in the annual inflation rate to 2.7% from 3.1% in&nbsp; October. The yearly rate of core inflation also slowed to 2.6% from 3%. But economists do not see a smooth downward trend in inflation.Commenting on the inflation data, Northlight Asset Management Chief Investment Officer Chris Zaccarelli said the November data was only one month’s figure and will likely fluctuate in the coming months.<blockquote>“But the main concern of Fed officials who are reluctant to keep cutting is that inflation is persistently high and won’t come down if they keep lowering interest rates, and at this point, that doesn’t look like it’s the case.”</blockquote>LPL Financial Chief Economist Jeffrey Roach also expects bumpy inflation readings in the next few months but expects it to drop to 2.5% by the year-end, allowing the Federal Reserve to cut rates a few times next year.Fund manager Louis Navellier hoped the Santa rally had begun, with nine trading days left in the year.&nbsp;<blockquote>“Expectations for an up market in the new year are the highest in 4 years. Ending the year at new highs is back on the table, as investors position themselves for a strong start to 2026.”</blockquote><h2 class="st-heading-2">Rate Cuts, AI Surge Likely To Be Market Theme</h2>The fears of the length of the bull market are ill-founded. According to a graphic shared by First Trust, the average bull market lasts 4.3 years and returns 151.4%. By this historical norm, the current market is still young: it is only a little over three years old, and the gain has been 89%.<img src="https://news.stocktwits-cdn.com/Screenshot_2025_12_19_at_3_17_26_AM_png_5713fd7ac4.webp" alt="Screenshot 2025-12-19 at 3.17.26 AM.png">Source: First TrustStrategists pin their hopes on strong profit growth and a resilient economy to support continued market gains next year. Zaccarelli sees further gains:<blockquote>“While next year will undoubtedly bring new challenges, heading into the end of the year, there should be room for the market to move higher as corporate profits are increasing, the GDP is growing and inflation (for now) remains in check.”</blockquote>In its 2026 outlook report, Morgan Stanley said it is overweight on U.S. equities due to resilient growth. The firm prefers U.S. large-caps despite market talk of the tech rally broadening as interest rates drop. It also looks for selective exposure to mid-cap stocks.<blockquote>“Economic conditions and market performance in 2026 may prove to be more U-shaped than K. The trough likely occurred in 2025, partially masked by stronger equity performance, with notably narrow leadership.”</blockquote>Despite the doom-and-gloom talk about artificial intelligence (AI), the technology is expected to boost the economy through increased spending and productivity gains.&nbsp;Retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, was ‘bearish’ as of early Friday. The&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust (DIA)</a> also elicited a ‘bearish’ sentiment, while retail traders were ‘extremely bearish’ on the&nbsp;<a href="https://stocktwits.com/symbol/IWM">iShares Russell 2000 ETF (IWM)</a>.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-had-ev-spotlight-this-year-this-chinese-rival-took-the-trophy/cLegpsgREAy">Tesla Stock Had The EV Spotlight This Year — This Chinese Rival Took The Trophy</a>

Night view of the illuminated exterior of New York Stock Exchange with a big American flag from the front facade, pictured in November 2024 in NYC, USA.

Soft Inflation Ushers Santa Onto Wall Street — Will Seasonal Trends Follow?

 Inflation eased, and yields fell, lifting stocks, but stretched valuations and cautious retail sentiment temper optimism.

Equity

 Inflation eased, and yields fell, lifting stocks, but stretched valuations and cautious retail sentiment temper optimism.


<ul class="summary-bullets"><li>The company also said that its Exovisse Artificial Tears have been developed in compliance with FDA mandates permitting nationwide over‑the‑counter distribution.</li><li>YD Bio now plans to conduct a small clinical trial in Taiwan to evaluate dry eye disease in collaboration with 3D Global Biotech.</li><li>The company is also advancing LSC Exosome Therapeutics through its collaboration with 3D Global Biotech for retinal and macular disorders.</li></ul>Taiwan-based biotechnology company YD Bio (YDES) said on Monday that it has reached a set of milestones that together mark its commercial entry into U.S. eye care.Following the announcement, shares of the firm traded 7% higher at the time of writing. &nbsp;The Taiwan-based company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ydesgroup.com/pressreleases/detail/23e04a99-0c62-4d1e-bd0e-ea782181d34c">said</a> that Exovisse Contact Lenses have obtained U.S. Food and Drug Administration clearance through its partner, 3D Global Biotech, confirming that the lenses are substantially equivalent to an already marketed device and can be sold in the U.S.The company also said that its Exovisse Artificial Tears have been developed in compliance with FDA mandates permitting nationwide over‑the‑counter distribution for eye hydration and dry eye comfort without individual FDA premarket approval.<h2 class="st-heading-2">Future Plans</h2>YD Bio now plans to conduct a small clinical trial in Taiwan to evaluate dry eye disease in collaboration with 3D Global Biotech and Taiwan-based contract research organization YC Biotech.The company is also advancing LSC Exosome Therapeutics through its collaboration with 3D Global Biotech for retinal and macular disorders. LSC exosome therapeutics refers to the use of exosomes derived from limbal stem cells (LSCs) for therapeutic purposes, particularly for conditions affecting the eye, like dry eye syndrome.The company said that it has enrolled its limbal stem cells and limbal stem cell exosomes in the FDA Drug Master File, establishing documentation to support future therapeutic development.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around YDES stayed within the ‘neutral’ territory while message volume remained at ‘extremely low’ levels.<figure class="image"><img style="aspect-ratio:586/61;" src="data:image/png;base64,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" width="586" height="61" alt="YDES’s Sentiment Meter and Message Volume as of 12:37 p.m. ET on Nov. 24, 2025 | Source: Stocktwits"><figcaption>YDES’s Sentiment Meter and Message Volume as of 12:37 p.m. ET on Nov. 24, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/YDES">YDES stock</a> is down by 20% this year and by about 22% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/pharma-bro-martin-shkreli-goes-short-on-capircor-therapeutics/cL5bQHUREQS">‘Pharma Bro’ Martin Shkreli Goes Short On Capricor Therapeutics – Stock Tumbles 17%</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

YD Bio Stock Rises On Entry Into US Eye Care Segment

The Taiwan-based company said that Exovisse Contact Lenses have obtained the U.S. Food and Drug Administration’s clearance through its partner 3D Global Biotech.

<ul class="summary-bullets"><li>The broader market has taken a beating since hitting fresh peaks in late October, with AI skepticism largely to blame.</li><li>Nebius announced a deal with Microsoft in early September to deliver dedicated capacity to the software giant from its new Vineland, New Jersey data center.</li><li>Retail has chosen to ignore the negativity and see the dip as a buying opportunity.</li></ul>Artificial intelligence (AI) infrastructure company Nebius Group N.V. (NBIS) “pain is not over,” according to CNBC Mad Money host Jim Cramer.&nbsp;<a href="https://stocktwits.com/symbol/NBIS">Nebius stock</a> is in deep correction territory, having declined about 40% since it hit a record high (intraday) of $141.10, set on Oct. 10.The broader market has taken a beating since hitting fresh peaks in late October, with AI skepticism largely to blame. Bearish commentary from high-profile investors such as Michael Burry has also heightened the panic.&nbsp;<h2 class="st-heading-2">Deals Raise Red Flag</h2>In a post on X, Cramer said, “I can't believe the capital destruction for press releases on deals and nothing else….NBIS, NJ, Microsoft.”&nbsp; The stock picker is referring to the multi-billion-dollar deal Nebius announced with Microsoft (MSFT) in early September to deliver dedicated capacity to the software giant from its new Vineland, New Jersey data center.When the deal was announced, Nebius' stock got a shot in the arm, jumping 49% in a single session.&nbsp; “In other words, stay away,” said Cramer.<h2 class="st-heading-2">AI Pessimism Abounds</h2>The main point of contention for skeptics is the AI bubble that has been building since late 2022, when OpenAI launched its large language model, ChatGPT. They question the logic of AI names, big and small, splurging investment dollars on infrastructure buildout, fearing the returns may not be commensurate&nbsp;with the investment.Of late, concerns of hyperscalers using accounting gimmicks to boost profitability have heightened. Burry, for one, called out Meta and Oracle in particular. After Nvidia reported stellar quarterly results, Burry questioned the Jensen Huang-led company’s stock-based compensation accounting.AI bears also point out the circular deals in the space, such as those involving Nvidia, in which customers buy computing power from the company, and the chipmaker, in turn, invests in them.<h2 class="st-heading-2">What Retail Feels About Nebius Stock</h2>On Stocktwits, retail sentiment toward the stock remained ‘bullish’ as of early Friday, and the message volume on the stream remained ‘high.’Retail sees the pullback as a buying opportunity. “Sold my previous position last night at 99.85 and regretted it. What a gift it’s back in the low 80s today,” a user chimed in.<stembedurl>https://stocktwits.com/ISmokeCigs/message/637027503</stembedurl>Another user shrugged the Nebius sell-off as a “market-driven” event. “The good thing is there is no Nebius-specific issue; if the market bounces, we will bounce,” they said.<stembedurl>https://stocktwits.com/Gemhunter6474/message/637011328</stembedurl>Nebius' stock is up over 200% despite the recent volatility.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dow-nasdaq-100-futures-tick-higher-but-fear-rules/cLPMOKfREaH">Dow, S&amp;P 500 Futures Tick Higher, But Fear Rules Amid Worst November Since 2008 — Strategists Split On Buying The Dip</a>

In this photo illustration, the Nebius logo is seen displayed on a smartphone screen. 

Jim Cramer Can’t Believe Nebius’ Capital Destruction As Stock Trades Deep In Bear Zone: ‘Pain Is Not Over’

Nebius stock is up over 200% despite the recent volatility, but it has shed 40% since its October highs.

<ul class="summary-bullets"><li>The contract value is roughly $210 million, scheduled to unfold across six years.</li><li>Under the program, Elbit will revamp core electronic assemblies that support Merkava tank’s functionality.</li><li>Elbit had a record backlog of&nbsp;$25.2 billion at the end of the third quarter.</li></ul>Elbit Systems (ESLT) announced on Wednesday that it has secured a series of new defense contracts from Israel’s Ministry of Defense. The agreements center on extensive improvements to the Merkava Main Battle Tank fleet and will be carried out over several years.<h2 class="st-heading-2">Contract Scope and Timeline</h2>The company said the combined value of the awards reaches roughly $210 million, marking a sizable commitment to long-term upgrades of the tank platform. The work is scheduled to unfold across six years.Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/ESLT">Elbit Systems’ stock</a> traded over 3% higher in Wednesday’s premarket. On Stocktwits, retail sentiment around the stock shifted to ‘neutral’ from ‘bearish’ territory the previous day. Message volume improved to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<figure class="image"><img style="aspect-ratio:928/99;" src="https://news.stocktwits-cdn.com/Screenshot_2025_11_19_061716_png_f0af82cc34.webp" alt="ESLT’s Sentiment Meter and Message Volume as of 06:00 a.m. ET on Nov. 19, 2025 | Source: Stocktwits" width="928" height="99"><figcaption>ESLT’s Sentiment Meter and Message Volume as of 06:00 a.m. ET on Nov. 19, 2025 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">System Overhauls&nbsp;</h2>Under the program, Elbit will revamp core electronic assemblies that support the tank’s functionality, allowing the armored vehicles to remain in service for an extended operational lifespan.&nbsp;A major part of the plan focuses on integrating new electro-optical technology that uses lightweight, AI-enabled systems. These upgraded units give crews improved day and night visibility, panoramic observation, and advanced tools for identifying and tracking threats.&nbsp;The fresh order comes even as the defense contractor reported a record backlog of&nbsp;$25.2 billion at the end of the third quarter. The company’s Q3 revenue increased 11% year-on-year to $1.92 billion.&nbsp;On Monday, the company landed a massive $2.3 billion international contract to be delivered over 8 years.&nbsp;ESLT stock has gained over 95% year-to-date and over 101% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-dgnx-stock-surge-13-today/cLPVEr1RE7p">Why Did DGNX Stock Surge 13% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Workers assemble Leopard 2A7 main battle tanks at the KNDS heavy weapons factory.

Elbit Systems' Grabs Fresh $210M Israeli Defense Order On Top Of A Record Backlog

The contract value is roughly $210 million, scheduled to unfold across six years.

The agreements center on extensive improvements to the Merkava Main Battle Tank fleet and will be carried out over several years.


<ul class="summary-bullets"><li>Oppenheimer upgraded Ondas' stock to ‘Outperform’ from ‘Perform’.</li><li>Demand for Ondas’ On-Air Solutions (OAS) platform remains robust, said Oppenheimer.</li><li>The company’s Q3 earnings surpassed analysts’ consensus estimates.&nbsp;&nbsp;</li></ul>Ondas Holdings Inc. (ONDS) drew the spotlight on Friday after Oppenheimer upgraded the stock to ‘Outperform’ from ‘Perform’ with a $12 price target. The move follows the company's report of a substantial increase in third-quarter revenue.&nbsp;The company’s third-quarter (Q3) revenue of $10.1 million and loss per share (EPS) of $0.03 both came in better than the analysts’ consensus estimate of $7.04 million and a loss of $0.05, respectively, according to Fiscal AI data.&nbsp;<h2 class="st-heading-2">Financial Strength</h2>Oppenheimer highlighted that Ondas’ Q3 revenue was more than six times the level from the same period in the previous year. Gross margins reached 26%, and the firm anticipates the company could approach 70% margins in the next few years as operational efficiencies improve.The company is entering this growth phase with a strong balance sheet, holding $840 million in pro forma cash, the firm stated.&nbsp;Demand for Ondas’ On-Air Solutions (OAS) platform remains robust, with an all-time high backlog of $22.2 million. Oppenheimer highlighted that this momentum underscores market confidence in the company’s offerings and growth trajectory.How Did Stocktwits Users React?&nbsp;<a href="https://stocktwits.com/symbol/ONDS">Ondas’s stock</a> traded over 14% higher on Friday mid-morning. On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory. Message volume improved to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<figure class="image"><img style="aspect-ratio:935/106;" src="https://news.stocktwits-cdn.com/Screenshot_2025_11_14_110439_png_eddf365957.webp" alt="ONDS’s Sentiment Meter and Message Volume as of 10:45 a.m. ET on Nov. 14, 2025 | Source: Stocktwits" width="935" height="106"><figcaption>ONDS’s Sentiment Meter and Message Volume as of 10:45 a.m. ET on Nov. 14, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user lauded the company’s business execution plan.&nbsp;<stembedurl>https://stocktwits.com/Igor73/message/636225316</stembedurl>The&nbsp;company also raised its revenue forecast for the full year 2025. It now expects the fiscal year’s revenue to come in at a minimum of $36 million, up from its previous guidance of $25 million.ONDS stock has gained over 199% in 2025 and over 931% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-stub-hub-s-stock-plunge-26-percent-today/cLPQW1mRE4j">Why Did StubHub’s Stock Plunge 26% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of Ondas Holdings Inc. 

Ondas Stock Receives Upgrade On Backlog Strength, Revenue Boom

Oppenheimer upgraded Ondas' stock to ‘Outperform’ from ‘Perform’.

Oppenheimer anticipates the company could approach 70% margins in the next few years as operational efficiencies improve.


Shares of Robo.ai (AIIO) jumped 23% on Tuesday morning after the company announced that a consortium led by Burkhan Capital has committed $300 million in investment into the company.The transaction is expected to close within the next 30 calendar days, provided customary conditions are met, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/burkhan-capital-llc-led-consortium-commits-to-investing-300-million-in-roboai-to-power-global-ai-and-robotics-platform-acceleration-302571005.html">said</a>. The investment will be used for U.A.E.-based Robo.ai’s platform that integrates smart devices into an AI-enabled ecosystem populated by blockchain, it said. The capital will also be used to strengthen the company’s market presence in the Middle East region and potentially expand into the global markets, including North America, Europe, and South Asia, it added.Burkhan Capital is a global investment firm that invests in AI and technology ventures. With offices in Miami and Abu Dhabi, it previously played a role in the Nasdaq IPO of edge AI computing company Blaize.Earlier this month, Robo.ai announced an investment in the decentralized physical infrastructure networks (DePIN) platform Arkreen to explore Web3 Technology. A few days before that, the firm also announced the establishment of a joint venture in the U.A.E. with Ewatt (Nanjing) Aerospace Technology Co., focused on the deployment of electric vertical take-off and landing (eVTOL) aircraft.The company aims to build a decentralized, AI-driven network platform that connects multiple smart devices, including smart vehicles, autonomous driving, robotics, electric vertical take-off and landing (eVTOL) aircraft, and intelligent logistics.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AIIO">AIIO stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.AIIO stock has more than tripled this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novavax-amends-deal-with-sanofi-broadens-partnership/chDDB6dR3BH">Novavax Amends Deal With Sanofi, Broadens Partnership</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Robo.ai Stock Soars On $300M Investment Commitment 

The transaction is expected to close within the next 30 calendar days, provided customary conditions are met, the company said.

CoreWeave Inc. (CRWV) has entered into a new deal with Nvidia Corp. (NVDA), under an existing long-term agreement by which Nvidia will gain access to CoreWeave’s unused cloud computing resources.&nbsp;The deal, signed on September 9, stems from a new order form added to the companies’ existing Master Services Agreement (MSA) signed in April 2023. The agreement's initial value is $6.3 billion.<a href="https://stocktwits.com/symbol/CRWV">CoreWeave stock</a> traded over 5% higher on Monday morning. On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory amid ‘normal’ message volume levels.&nbsp;<figure class="image"><img style="aspect-ratio:931/100;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_15_100549_png_cce3162168.webp" alt="CRWV’s Sentiment Meter and Message Volume as of 10:00 a.m. ET on Sep. 15, 2025 | Source: Stocktwits" width="931" height="100"><figcaption>CRWV’s Sentiment Meter and Message Volume as of 10:00 a.m. ET on Sep. 15, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user lauded the development.&nbsp;<stembedurl>https://stocktwits.com/angelinvesting369/message/628679751</stembedurl>Another user highlighted&nbsp;Deutsche Bank’s endorsement of the stock.&nbsp;<stembedurl>https://stocktwits.com/Profitrip/message/628678314</stembedurl>Nvidia will now be contractually obligated to purchase any leftover cloud capacity that CoreWeave cannot sell to its own customers, through April 13, 2032.&nbsp;The structure allows Nvidia to tap into this excess infrastructure as needed, potentially increasing efficiency and reducing resource shortages during periods of peak demand. The MSA will continue until all active orders have either expired or been terminated, or until the agreement is canceled.&nbsp;Deutsche Bank analyst Brad Zelnick issued a "Catalyst Call: Buy" for CoreWeave as a short-term investment opportunity, according to TheFly. The firm identified several near-term drivers that could propel the company's revenue and share performance upward, particularly over the next two quarters.Zelnick points to a strong and growing appetite for AI infrastructure, noting that demand continues to outpace supply. CoreWeave stock has gained over 195%&nbsp;so far since its listing in March.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/crowdstrike-meta-launch-new-ai-security-tool/chwwab4RdUf">CrowdStrike, Meta Launch New AI Security Tool</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of CoreWeave Inc. (NASDAQ:CRWV) on August 8, 2025, in Chongqing, China. 

CoreWeave Stock Just Shot Up 5% Today And There’s An Nvidia Angle – Find Out More

The company has entered into a new deal with Nvidia under which the chipmaker will be contractually obligated to purchase any leftover cloud capacity that CoreWeave cannot sell to its own customers, through April 13, 2032. 

CoreWeave Inc. (CRWV) stock gained attention on Wednesday, drawing significant investor interest after the shares rose 16% on Wednesday’s morning trade.&nbsp;The company had announced the launch of CoreWeave Ventures on Tuesday, a new program designed to support startups and entrepreneurs shaping the future of artificial intelligence and next-generation computing technologies.<a href="https://stocktwits.com/symbol/CRWV">CoreWeave stock</a> traded over 16% higher on Wednesday, after the morning bell. On Stocktwits, retail sentiment toward the stock shifted to ‘neutral’ from ‘bearish’ territory the previous day amid ‘normal’ message volume levels.&nbsp;<figure class="image"><img style="aspect-ratio:947/112;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_10_090854_png_67ebc3afd5.webp" alt="CRWV’s Sentiment Meter and Message Volume as of 09:35 a.m. ET on Sep. 10, 2025 | Source: Stocktwits" width="947" height="112"><figcaption>CRWV’s Sentiment Meter and Message Volume as of 09:35 a.m. ET on Sep. 10, 2025 | Source: Stocktwits</figcaption></figure>The stock saw a 964% surge in user message count over the past month. A Stocktwits user highlighted the fact that the company has deployed 250,000 graphics processing units (GPUs).&nbsp;<stembedurl>https://stocktwits.com/dreamer66/message/628109458</stembedurl>Another user commented that the AI trade is still intact.&nbsp;<stembedurl>https://stocktwits.com/noonehasthisusername/message/628113904</stembedurl>As the need for AI-ready infrastructure continues to surge across industries, CoreWeave’s venture arm will offer funding, infrastructure access, and strategic guidance to help emerging companies accelerate product development and market readiness.The initiative offers access to CoreWeave’s purpose-built AI cloud platform, production-grade testing environments, and advice informed by its close ties with AI-driven enterprises.On September 3, the company entered into a definitive deal to acquire OpenPipe Inc., a startup specializing in reinforcement learning tools used to train AI agents. The integration of OpenPipe’s reinforcement learning system positions CoreWeave to offer a broader AI training stack, especially as demand for custom, self-improving agents continues to climb.In the second quarter, the AI hyperscaler reported a&nbsp;207% year-on-year increase in revenue to $1.21 billion, beating the consensus estimate of $1.08 billion, according to Fiscal AI data.&nbsp;Coreweave stock has gained over 150% so far since its listing in March.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/oracle-ai-surge-triggers-wall-street-upgrade-and-price-target-hikes/chwkOXpRduQ">Oracle’s AI Surge Triggers Wall Street Upgrade And Price Target Hikes</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of AI cloud-computing startup CoreWeave is displayed on a smartphone screen on May 16, 2025 in Suqian, Jiangsu Province of China. 

CoreWeave Surged 16% Today And Retail Can’t Stop Talking About The Stock – Find Out More

CoreWeave saw a 964% surge in Stocktwits retail chatter over the past month.

CoreWeave Inc. (CRWV) received mixed reactions from Wall Street analysts after the company released its second-quarter (Q2) earnings, with some voicing concerns over narrow margins and the upcoming IPO (initial public offering) lock-in expiry on August 14.Stifel raised its price target to $120 from $115 but kept its ‘Hold’ rating, as per TheFly.&nbsp; The firm cited stronger-than-expected guidance for the third quarter (Q3) and fiscal 2025 but flagged margin concerns. It also warned of pressure from dilution tied to the Core Scientific deal and the impending IPO lock-up expiration.In July, CoreWeave had&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/coreweave-doubles-down-on-ai-ambitions-with-power-heavy-core-scientific-merger/chFtZ9CR59g">agreed to acquire</a> the data center infrastructure company, Core&nbsp;Scientific Inc. (CORZ), in an all-stock deal, valued at about $9 billion.<a href="https://stocktwits.com/symbol/CRWV">CoreWeave stock</a> traded 19% lower on Wednesday mid-morning. On Stocktwits, retail sentiment toward the stock improved to ‘extremely bullish’ from ‘bullish’ territory the previous day. Message volume jumped to ‘extremely high’ from ‘normal’ levels in 24 hours.&nbsp;<figure class="image"><img style="aspect-ratio:955/109;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_13_110129_png_db16d0c424.webp" alt="CRWV’s Sentiment Meter and Message Volume as of 10:50 a.m. ET on Aug. 13, 2025 | Source: Stocktwits" width="955" height="109"><figcaption>CRWV’s Sentiment Meter and Message Volume as of 10:50 a.m. ET on Aug. 13, 2025 | Source: Stocktwits</figcaption></figure>The stock experienced a 462% surge in user message count over 24 hours, as of Wednesday morning. A bullish Stocktwits user said&nbsp;the&nbsp;lock-up expiration event is the only fear factor in the near term.<stembedurl>https://stocktwits.com/WallStreetWraith/message/624959436</stembedurl>Another user said they find the earnings report more bullish.<stembedurl>https://stocktwits.com/eatsleeptrades/message/624957347</stembedurl>Wells Fargo lifted its target to $105 while maintaining an ‘Equal Weight’ stance. The brokerage highlighted healthy demand and a rising backlog, but noted that CoreWeave continues to post negative earnings per share amid aggressive capital expenditures.BofA trimmed its target from $185 to $168, retaining a ‘Neutral’ rating. The firm praised CoreWeave’s strong positioning in the AI infrastructure space but pointed to unanswered questions around its proposed acquisition of Core Scientific, ongoing regulatory uncertainty, and volatility risks tied to the looming lock-up expiry.The company reported a loss per share of $0.27 in Q2, narrower than the year-ago loss of $1.62. However, the loss per share was wider than the consensus estimate of a loss of $0.20, as per Fiscal AI data. Meanwhile, revenue climbed 207% year-on-year to $1.21 billion, beating the consensus estimate of $1.08 billion.&nbsp;CoreWeave stock has gained over 205% so far since its listing in March.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cineverse-banyan-launch-microco/chrCguARd9O">Cineverse, Banyan Launch AI‑Native Microseries Studio, MicroCo</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did CoreWeave Stock Fall A Whopping 19% Today? Find Out More

The company received a slew of price target updates from Wall Street following its earnings release and notably, not everyone appears to be on the same page.

CoreWeave, Inc. (CRWV) stock fell sharply in Tuesday’s extended trading after the data center operator’s earnings miss and the looming initial public offering (IPO) lockup expiration dented sentiment toward the stock.On Stocktwits, retail traders largely shrugged off the stock drop.&nbsp;<a href="https://stocktwits.com/symbol/CRWV">CoreWeave’s stock</a> elicited an ‘extremely bullish’ (94/100) reaction from watchers of the stock on the platform, an improvement from the ‘bullish’ mood seen a day ago.The message volume on the Stream also spurted to extremely high levels.&nbsp;<figure class="image"><img style="aspect-ratio:621/51;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_12_at_9_57_56_PM_png_a1454156f5.webp" alt="Screenshot 2025-08-12 at 9.57.56 PM.png" width="621" height="51"><figcaption>CRWV sentiment and message volume as of 9:55 p.m. ET, Aug. 12 | source: Stocktwits</figcaption></figure>The Livingston, New Jersey-based company reported a loss per share of $0.27 for the second quarter of the fiscal year 2025, narrower than the year-ago loss of $1.62. The quarterly loss per share, however, was wider than the Fiscal.ai-compiled consensus estimate (-$0.20).During the call, CFO Nitin Agrawal stated that the company’s cost of revenue and technology and infrastructure spending increased as it ramped up investments in data center and server infrastructure to meet growing customer demand, according to a transcript provided by Koyfin.Revenue climbed 207% year-over-year (YoY) to $1.21 billion, beating the consensus estimate of $1.08 billion.&nbsp;CEO Michael Intrator said, “Our strong second quarter performance demonstrates continued momentum across every dimension of our business,” adding that the company was scaling rapidly to meet “unprecedented” artificial intelligence (AI) demand.CoreWeave stated that its revenue backlog stood at $30.1 billion as of the end of the June quarter.Capital expenditures for the quarter totaled $2.9 billion, representing an increase of over $1 billion from the previous quarter. The company expects capital expenditures to be between $2.9 billion and $3.4 billion in the fourth quarter.During the earnings call, the company guided third-quarter revenue to be in the range of $1.26 billion to $1.30 billion, and adjusted operating income to be in the range of $160 million to $190 million. Analysts, on average, expect&nbsp;the company to report revenue of $1.25 billion for the quarter.CoreWeave has raised its full-year revenue guidance to a range of $5.15 billion to $5.35 billion, up from a previous range of $4.9 billion to $5.1 billion, citing continued strong customer demand. The outlook aligned with the $5.04 billion consensus estimate. The company maintained its adjusted operating income guidance at $800 million to $830 million.&nbsp;It also maintained its full-year capital expenditure (Capex) guidance at $20 billion to $23 billion.CNBC's Mad Money host and stock picker, Jim Cramer, was left impressed with the results. “Coreweave is good,” he said in a post on X. But he cautioned regarding the lockup expiration. “There are a lot of people who have found money, and they are going to take it off the table,” he said.A retail watcher of the stock on Stocktwits noted that the adverse stock reaction may be due to the company’s high debt levels. “But I expect upgrades to come soon because of the pure revenue explosion ahead,” they said.<stembedurl>https://stocktwits.com/EderT/message/624887619</stembedurl>On the call, Agrawal said, “We expect our Q3 interest expense to be in the range of $350 million to $390 million impacted by increased debt to support our demand-led CapEx growth.”&nbsp;Another user recommended buying the dip.<stembedurl>https://stocktwits.com/oldmoneymkr/message/624887155</stembedurl>CoreWeave stock is up over 270% since its late March IPO.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tonix-pharma-best-day-since-march-fda-fibromyalgia-drug-approval-retail-optimistic/chrzHdwRdJu">Tonix Pharma Scores Best Day Since March On Hopes For First New Fibromyalgia Drug Approval in 16 Years; Retail’s Optimistic</a>

2025/07/18: In this photo illustration, the logo of CoreWeave, a U.S.-based AI cloud computing startup, is displayed on a smartphone screen. 

Jim Cramer Praises CoreWeave After AI Demand Fuels Q2 Revenue Beat, Guidance Hike — Retail Traders Bullish Even As Other Worries Linger

CFO Nitin Agrawal said the company’s cost of revenue and technology and infrastructure spend increased as it ramped up investments in data center and server infrastructure to meet growing customer demand.

ONEQ
Fidelity Nasdaq Composite Index ETF

Feed

News

Sentiment

Fundamentals

Info

Latest ONEQ News

ONEQFidelity Nasdaq Composite Index ETF